# GLOW blend (GHK-Cu + BPC-157 + TB-500)

Source: https://aminodesk.com/library/glow-blend
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

GLOW is a seller's name for three peptides mixed in one vial: GHK-Cu, BPC-157 and TB-500. It is sold for skin, hair and recovery together. No trial has tested the mixture, and a mixed vial falls outside the 2026 compounding policy.

- **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved.
- **Evidence grade:** D for the combination
- **What is in it:** GHK-Cu, BPC-157 and TB-500
- **Established human dose:** none

## What it is

A premixed vial that adds the copper peptide [GHK-Cu](https://aminodesk.com/library/ghk-cu) to the two repair peptides in the [Wolverine blend](https://aminodesk.com/library/wolverine-blend), [BPC-157](https://aminodesk.com/library/bpc-157) and [TB-500](https://aminodesk.com/library/tb-500). The name does not describe a tested product.

## What the evidence shows

There is no trial of this blend.

The evidence that exists applies to each ingredient studied separately. For BPC-157 and TB-500 it is almost entirely animal work with no completed controlled human trials. The human evidence for GHK-Cu is for products applied to the skin, which is a different thing from injecting it; see the GHK-Cu page for both.

"Synergy" in blend marketing means the seller expects the combination to work better. It does not mean anyone measured it.

## Legal status

In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it.

GLOW has two problems under that policy. It holds more than one active ingredient, and GHK-Cu is not one of the six peptides the policy covers. A seller offering it is working outside the policy or is not a licensed compounding pharmacy.

## Reported dosing

**No dose has been established for this blend.**

No human trial has tested it. The schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

## Safety

- **You cannot tell what worked.** If you improve, you have learned nothing about which ingredient to keep.
- **You cannot tell what went wrong.** A reaction means stopping everything, with no way to find the cause except starting over one at a time.
- **The mixture itself is unstudied.** Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations.
- **Quality is a separate risk.** A pharmacy following the policy closely will not make a blend, so the product comes from outside that system.

**Copper accumulates.** Anything based on GHK-Cu delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, which is a conversation for a clinician.

## Common questions

### What is in the GLOW blend?

GHK-Cu, BPC-157 and TB-500, mixed in one vial.

### Is the GLOW blend legal?

Not under the October 2026 policy. That policy allows one active ingredient per compounded product, and GHK-Cu is not among the six peptides it covers.

### Has the GLOW blend been tested in people?

No. There is no human trial of the mixture.

## Sources

- [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf)
- [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/)
- [Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy](https://www.bipc.com/compounding-peptides-what-compounding-pharmacies-need-to-know-about-the-hhs-interim-enforcement-discretion-policy-for-six-peptides)
- [Healio: advisory committee discussion, including the combination-use concern raised on TB-500](https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides)

All three repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). To keep a private record of what you take, use the [dose and progress log](https://aminodesk.com/glp1-log).

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
